Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Teclistamab
Plasma Cell Myeloma
Anne Louise Tølbøll Sørensen
P4
BB
(66)
Tislelizumab
Breast Cancer
National University Hospital, Singapore
P4
BB
(66)
Tislelizumab
Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P4
BB
(66)
AK105
Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
P3
BB
(66)
Amrecibart
Atrial Fibrillation
Regeneron Pharmaceuticals
P3
BB
(66)
Atezolizumab
Castration-Resistant Prostate Carcinoma
Cancer Research UK
P3
BB
(66)
Blinatumomab
Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
P3
BB
(66)
Blinatumomab
B Lymphoblastic Lymphoma
Children's Oncology Group
P3
BB
(66)
Blinatumomab
Down Syndrome
National Cancer Institute (NCI)
P3
BB
(66)
Cenvacibart
Atrial Fibrillation
Regeneron Pharmaceuticals
P3
BB
(66)
Cetuximab
Head And Neck Cancer
Pfizer
P3
BB
(66)
Concizumab
Hemophilia B
Novo Nordisk A/S
P3
BB
(66)
Divozilimab
Multiple Sclerosis
Biocad
P3
BB
(66)
Durvalumab
Small Cell Lung Carcinoma
PrECOG, LLC.
P3
BB
(66)
Girentuximab
Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
P3
BB
(66)
Gls-010
Classic Hodgkin Lymphoma
Guangzhou Gloria Biosciences Co., Ltd.
P3
BB
(66)
Humax-Cd20
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PETHEMA Foundation
P3
BB
(66)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Triple-Negative Breast Carcinoma
Fudan University
P3
BB
(66)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
HR+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
National Cancer Institute (NCI)
P3
BB
(66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Juvenile Myelomonocytic Leukemia
Masonic Cancer Center, University of Minnesota
P3
BB
(66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Leukemia
University of Chicago
P3
BB
(66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Richter Transformation
SWOG Cancer Research Network
P3
BB
(66)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Skin Squamous Cell Carcinoma
Regeneron Pharmaceuticals
P3
BB
(66)
immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens KLK2 (kallikrein-2, kallikrein related peptidase 2, kallikrein 2 prostatic) and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific, bivalent
Castration-Resistant Prostate Carcinoma
Janssen Research & Development, LLC
P3
BB
(66)
Showing 251 to 275 of 6,371 assets
Previous
Page 11 of 255
Next